Olmesartan medoxomil: The seventh angiotensin receptor antagonistGARDNER, Stephanie F; FRANKS, Amy M.The Annals of pharmacotherapy. 2003, Vol 37, Num 1, pp 99-105, issn 1060-0280, 7 p.Article

Comparison of Olmesartan Medoxomil Versus Amlodipine Besylate on Regression of Ventricular and Vascular HypertrophyROSENDORFF, Clive; DUBIEL, Robert; JIANBO XU et al.The American journal of cardiology. 2009, Vol 104, Num 3, pp 359-365, issn 0002-9149, 7 p.Article

Effects of Olmesartan medoxomil on systolic blood pressure and pulse pressure in the management of hypertensionGILES, Thomas D; ROBINSON, Thomas D.American journal of hypertension. 2004, Vol 17, Num 8, pp 690-695, issn 0895-7061, 6 p.Article

Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazideCHRYSANT, Steven G; WEBER, Michael A; WANG, Antonia C et al.American journal of hypertension. 2004, Vol 17, Num 3, pp 252-259, issn 0895-7061, 8 p.Article

Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic : an updateCHRYSANT, S. G; DIMAS, B; SHIRAZ, M et al.Journal of human hypertension. 2007, Vol 21, Num 9, pp 699-708, issn 0950-9240, 10 p.Article

Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertensionCHARYSANT, S. G; MARBURY, T. C; ROBINSON, T. D et al.Journal of human hypertension. 2003, Vol 17, Num 6, pp 425-432, issn 0950-9240, 8 p.Article

Blood Pressure-Lowering Effects of Angiotensin Receptor Antagonist Monotherapy and in Combination with Other Anti-Hypertensive Drugs in Primary Care Settings in JapanKUSHIRO, Toshio; SAITO, Ikuo; HIRATA, Koji et al.Clinical and experimental hypertension (1993). 2009, Vol 31, Num 2, pp 127-141, issn 1064-1963, 15 p.Article

Management of Hypertension in Patients With Diabetes Using an Amlodipine-, Olmesartan Medoxomil-, and Hydrochlorothiazide-Based Titration RegimenVENKATA RAM, C; SACHSON, Richard; LITTLEJOHN, Thomas et al.The American journal of cardiology. 2011, Vol 107, Num 9, pp 1346-1352, issn 0002-9149, 7 p.Article

Pharmacokinetic properties and bioequivalence of olmesartan medoxomil/hydrochlorothiazide in healthy Korean male subjectsCHANGYUN JIN; JEON, Ji-Young; IM, Yong-Jin et al.International journal of clinical pharmacology and therapeutics. 2014, Vol 52, Num 1, pp 64-72, issn 0946-1965, 9 p.Article

Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertensionNEUTEL, J. M; SMITH, D. H. G; SILFANI, T. N et al.Journal of human hypertension. 2006, Vol 20, Num 4, pp 255-262, issn 0950-9240, 8 p.Article

A Double-Blind, Dose-Response Study of the Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescents with HypertensionHAZAN, Lydie; HERNANDEZ RODRIGUEZ, Oscar A; BHORAT, As'ad E et al.Hypertension (Dallas, Tex. 1979). 2010, Vol 55, Num 6, pp 1323-1330, issn 0194-911X, 8 p.Article

Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteersHUBER, Matthias; BOLBRINKER, Juliane; KREUTZ, Reinhold et al.Clinical and experimental hypertension (1993). 2006, Vol 28, Num 7, pp 631-643, issn 1064-1963, 13 p.Article

Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy modelsNAKAMURA, Hiroaki; INOUE, Tatsuya; ARAKAWA, Naohisa et al.European journal of pharmacology. 2005, Vol 512, Num 2-3, pp 239-246, issn 0014-2999, 8 p.Article

Entéropathie sévère avec atrophie villositaire associée à la prise d'olmésartan médoxomil = Severe Enteropathy with Villous Atrophy Olmesartan Medoxomil-associatedNUNGE, Débora; EOCHE, Matthieu; FUMERY, Mathurin et al.Thérapie (Paris). 2013, Vol 68, Num 6, pp 419-421, issn 0040-5957, 3 p.Article

Modifications by Olmesartan medoxomil treatment of the platelet protein profile of moderate hypertensive patientsSACRISTAN, Daniel; MARQUES, Maria; TAMARGO, Juan et al.Proteomics. Clinical applications (Print). 2008, Vol 2, Num 9, pp 1300-1312, issn 1862-8346, 13 p.Article

Le medicament du mois : Olmesartan medoxomil hydrochlorothiazide (Olmetec Plus® ou Belsar Plus®) = Olmesartan medoxomil hydroclorothiazideLANCELLOTTI, P.RMLG. Revue médicale de Liège. 2007, Vol 62, Num 3, pp 175-179, issn 0370-629X, 5 p.Article

Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertensionRUMP, L. C; GIRERD, X; SELLIN, L et al.Journal of human hypertension. 2011, Vol 25, Num 9, pp 565-574, issn 0950-9240, 10 p.Article

Development of a CZE Method for the Determination of Olmesartan Medoxomil in TabletsCELEBIER, Mustafa; ALTINÖZ, Sacide.Chromatographia (Wiesbaden). 2007, Vol 66, Num 11-12, pp 929-933, issn 0009-5893, 5 p.Article

Clinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonistYOSHIDA, Kazunori; KOHZUKI, Masahiro.Cardiovascular drug reviews (Print). 2004, Vol 22, Num 4, pp 285-308, issn 0897-5957, 24 p.Article

Olmesartan medoxomil: An angiotensin II-receptor blockerBROUSIL, Julie A; BURKE, John M.Clinical therapeutics. 2003, Vol 25, Num 4, pp 1041-1055, issn 0149-2918, 15 p.Article

Hydrolysis of angiotensin II receptor blocker prodrug olmesartan medoxomil by human serum albumin and identification of its catalytic active sitesMA, Shen-Feng; ANRAKU, Makoto; IWAO, Yasunori et al.Drug metabolism and disposition. 2005, Vol 33, Num 12, pp 1911-1919, issn 0090-9556, 9 p.Article

The Use of Modeling and Simulation to Guide Clinical Development of Olmesartan Medoxomil in Pediatric SubjectsSALAZAR, D. E; SONG, S. H; SHI, J et al.Clinical pharmacology and therapeutics. 2012, Vol 91, Num 2, pp 250-256, issn 0009-9236, 7 p.Article

Estrogen or the AT1 antagonist olmesartan reverses the development of profound hypertension in the congenic mRen2.Lewis ratCHAPPELL, Mark C; GALLAGHER, Patricia E; AVERILL, David B et al.Hypertension (Dallas, Tex. 1979). 2003, Vol 42, Num 4, pp 781-786, issn 0194-911X, 6 p., 2Article

Le médicament du mois : Olmésartan Médoxomil (Belsar® ou Olmetec®) = Olmesartan medoxomilKRZESINSKI, J. M; SCHEEN, A. J.RMLG. Revue médicale de Liège. 2004, Vol 59, Num 10, pp 607-611, issn 0370-629X, 5 p.Article

DEVELOPMENT OF A STABILITY-INDICATING UPLC METHOD FOR DETERMINATION OF OLMESARTAN MEDOXOMIL AND ITS DEGRADATION PRODUCTS IN ACTIVE PHARMACEUTICAL INGREDIENT AND DOSAGE FORMSRAJ, Shiva; KUMARI, K. Siva; NARASIMHA RAO, A et al.Journal of liquid chromatography & related technologies. 2012, Vol 35, Num 5-8, pp 1011-1026, issn 1082-6076, 16 p.Article